Shire Settles Generic Adderall Spat With Sandoz

Law360, New York (October 13, 2009, 4:46 PM EDT) -- Irish drugmaker Shire PLC said Tuesday it had settled patent litigation over Sandoz Inc.'s abbreviated new drug application to market a generic version of Shire's attention deficit hyperactivity disorder drug Adderall XR.

The settlement agreement provides Sandoz with a license to market its own generic versions of Adderall XR in the United States once it receives approval by the U.S. Food and Drug Administration, with Shire receiving royalties from those sales, Shire said in press release.

Sandoz did not immediately respond to requests for comment Tuesday....
To view the full article, register now.